CAS: 5291-32-7; 2-(Hydroxymethyl)-2-(Methoxymethyl)Quinuclidin-3-One

该化合物是一种双环化合物,其结构内含有氮原子,是氨环化合物的特征,这种物质既含有氢氧甲基,也含有甲基甲基和甲基甲氧的功能组,有助于其在有机合成中的再活性和潜在应用.双环框架提供了一个僵硬的结构,能够影响化合物的物理特性,例如溶性与熔点.氯酮功能组的存在表明在核生殖作用增加反应中具有再活动的潜力.此外,该化合物由于其结构特征,可能展示生物活动,使其对医药化学感兴趣.其独特的功能组和双环结构组合还可能允许各种修改,导致特定应用中具有特定特性的衍生物.与许多有机化合物一样,在实验室与该物质打交道时,应当考虑安全数据和处理预防措施.

结构式图片

欧盟法规

C&L通报

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-11285169-B2
    优先权日:2013-03-13
    标题 :Methods for modulating chemotherapeutic cytotoxicity
    发明人:ROBERTS DAVID D; SOTO PANTOJA DAVID R
    权利人:US HEALTH
    摘要:Methods of reducing cytotoxicity of a chemotherapeutic agent to non-cancer cells by administering to a subject with cancer an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent, such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are provided. Example disclosed methods reduce cardiotoxicity. In one example, the methods include administering to a subject with cancer an effective amount of a CD47 antisense morpholino oligonucleotide and an anthracycline such as doxorubicin. Methods of increasing cytotoxicity of a chemotherapeutic agent in cancer cells by administering to a subject with a tumor an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are also provided. In some embodiments, the inhibitor of CD47 signaling is administered to the subject before, during, or after the administration of the DNA damaging agent.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Michaeli O, Luz I, Vatarescu M, Manko T, Weizman N, Korotinsky Y, Tsitrina A, Braiman A, Arazi L, Cooks T. APR-246 as a radiosensitization strategy for mutant p53 cancers treated with alpha-particles-based radiotherapy. Cell Death Dis. 2024 Jun 18;15(6):426. doi: 10.1038/s41419-024-06830-3.
    2: Strandgren C, Wiman KG. Therapeutic targeting of TP53 nonsense mutations in cancer. Ups J Med Sci. 2024 May 27;129. doi: 10.48101/ujms.v129.10719.
    3: Santini V, Stahl M, Sallman DA. TP53 Mutations in Acute Leukemias and Myelodysplastic Syndromes: Insights and Treatment Updates. Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e432650. doi: 10.1200/EDBK_432650. 12(2):e0340523. doi: 10.1128/spectrum.03405-23. Epub 2024 Jan 17.

    合成参考文献


    参考文献:10.18632/oncotarget.5385
    摘要:Li XL, Zhou J, Chan ZL, Chooi JY, Chen ZR, Chng WJ. PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms. Oncotarget. 2015 Nov 03;6(34):36689–99.
    参考文献:10.1186/s12885-015-1667-1
    摘要:Grellety T, Laroche-Clary A, Chaire V, Lagarde P, Chibon F, Neuville A, Italiano A. PRIMA-1(MET) induces death in soft-tissue sarcomas cell independent of p53. BMC Cancer. 2015 Oct 13;15():684.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知